Stämm develops a next-generation biomanufacturing platform that pairs naturally occurring microfluidics and laminar flow with 3D-printing to enable continuous and autonomous mammalian cell production. Led by CEO Yuyo Llamazares and based in Buenos Aires, the company employs a team of more than 100 people. Following its Series A, Stämm plans to prepare for commercialization and to further develop biopharma partnerships into pilot scale. The company will also use funds to enhance operational infrastructure, continue growing its team, and deepen its international presence. The article does not report revenue or other operating metrics.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022